Home›Trial›NCT07221877
🔬NCT07221877Phase 4RECRUITING

A Study to Evaluate the Effect of KarXT on Urological Safety

Study Summary

The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.

Conditions
Schizophrenia
Interventions / Drugs
Xanomeline/trospium chloride
View on ClinicalTrials.gov ↗
Sponsor
BMY
Bristol-Myers Squibb
Oncology
F35/100
Study Details
Enrollment60 participants
Primary Completion—
Lead SponsorBristol-Myers Squibb
Data Retrieved2026-04-11 04:08:14.745862+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.